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Breastfeeding in the treatment of children
with phenylketonuria
Viviane C. Kanufre,1 Ana L. P. Starling,2 Ennio Leão,3 Marcos J. B. Aguiar,4
Jacqueline S. Santos,5 Rosângelis D. L. Soares,6 Adriana M. Silveira7
Abstract
Objective: To evaluate the effect of breastmilk as a source of phenylalanine (phe) on levels of this amino acid and
on growth in phenylketonuric infants.
Methods: The study recruited 35 breastfed phenylketonuric infants and compared their results with those of 35
infants fed on commercial,milk-based formula. The groupswere paired for sex and age atweaning frombreastfeeding.
Data were analyzed up until cessation of breastmilk or for 12 months’ follow-up. The breastfed group were given a
“special formula” free of phe, by bottle every 3 hours, and breastmilk at will during the intervals. Levels of phe in the
blood, collectedweekly up to6months and fortnightly up to1year deage,were analyzedwhile breastfeeding continued.
The twogroupswere compared in termsof the time taken for the levels of phe inblood to return tonormal after treatment
was started, using the Wilcoxon test. Anthropometric data were compared with Student’s t paired test in the form of z
scores. The phe assays were analyzed throughout breastfeeding.
Results: The median time taken for phe levels to return to normal was 8 days for the breastfed group and 7 days
for the control group. The phe assay results were normal in 87% of tests for the breastfed group and in 74.4% for the
control group. The majority of children in both groups exhibited a z score > -2 on anthropometric examination.
Conclusions: Continuation of breastfeeding, during the treatment, proved adequate for metabolic control and
growth in children with phenylketonuria.
J Pediatr (Rio J). 2007;83(5):447-452: Breastfeeding, phenylketonuria, phenylalanine.
Introduction
Phenylketonuria (PKU) is an autosomal recessive genetic
disease, characterized by either a deficiency or even absence
of phenylalanine hydroxylase enzyme activity, which pre-
vents hydroxylation of phenylalanine (phe) into tyrosine. The
increased levels of phe in the blood then lead to central ner-
vous systemabnormalities, causing irreversiblemental retar-
dation.1
The Minas Gerais State Neonatal Screening Program
(PETN-MG-ProgramaEstadual de TriagemNeonatal deMinas
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Gerais), which is managed by the Center for Actions and
Research in Diagnostic Support (NUPAD - Núcleo de Ações e
Pesquisa em Apoio Diagnóstico) at the Medical Faculty of the
Universidade Federal de Minas Gerais (FM-UFMG), is respon-
sible for neonatal screening in the state of Minas Gerais, Bra-
zil. All children with phe levels ≥ 4 mg/dL are referred to the
Special Genetics Service at the Hospital das Clínicas, UFMG
(SEG-HC-UFMG), for diagnostic elucidation and treatment, if
needed.2 According to the Brazilian HealthMinistry’s protocol
(Directive SAS/MS 847/2002), all children with levels of phe
in blood≥ 10mg/dLmust be treated. Treatment is based on a
diet that restricts phe, associated with a protein substitute to
makeupdaily protein requirements, in particular.2-4 Theblood
phe levels considered adequate for phenylketonuric patients
during their first year of life should be≥ 2mg/dL≤ 6mg/dL.5
Since phe is also an essential amino acid for phenylketonuric
patients, their diet must contain the correct amount, making
it possible to maintain blood levels within limits considered
safewhile alsomaintaining the patients’ growth and develop-
ment within the parameters of normality.3 The traditional
treatment for PKU includes the recommendation to withdraw
breastmilk (BM) due to the difficulties involved in quantifying
children’s phe intake and, consequently, in controlling their
blood levels. More recent studies have been demonstrating
that it is possible to control phe blood levels using BMas a phe
source.6-9 The objective of this study was to evaluate the
effect of BM as a phe source on the blood levels of this amino
acid and on growth in children with PKU, compared with the
traditional treatment.
Methods
A historic, prospective, paired cohort study was carried
out. The sample was made up of 70 infants, 35 who had con-
tinued breastfeeding, born between January 2000 and April
2005, and accounting for 70% of the population diagnosed
during that period, and 35 controls who were not breastfed,
born between1993and1999. All of the infantswere screened
by the PETN-MG and were being treated at the SEG-HC-
UFMG. The breastfeeding group was composed of children
who were being naturally breastfed on the day of diagnosis,
had been born full term, with birth weight ≥ 2,500 g, with no
chronic diseases, and who started treatment by 40 days and
continued breastfeeding up to at least 30 days after the start
of therapy.
This groupwas compared to a control group, composed of
35 infants with PKU who had been given traditional treat-
ment, paired for sex and age at breastfeeding cessation.
These childrenwere selectedby lots froma list of possible con-
trols who met the same inclusion criteria described above.
The variables of each pair were compared up to the age at
which the child in the breastfeeding group ceasedbreastfeed-
ing. After this point, the pair were no longer entered into
analyses, and children were aged as close as possible to each
other. Consultations and phe blood assays were carried out
weekly until 6 months of age and fortnightly thereafter up to
1 year.
The parents or guardians signed an informed consent
form, and the study was approved by the Research Ethics
Committee at the Universidade Federal de Minas Gerais
(COEP-UFMG).
Until January of 2000, at the SEG-HC-UFMG all children
with blood phe levels ≥ 10 mg/dL were treated using a com-
mercial infant formula, given by bottle, and BM was with-
drawn. From that point onwards, children that fulfilled the
inclusion criteria were enrolled on the study, following a spe-
cific protocol. The treatment was based on research that has
beenpublished on the theme,which demonstrated that it was
possible to continue breastfeeding while treating PKU.6-8,10
Blood samples for assaying concentrations of the amino
acid were taken by venous puncture, and phe assay was by
ultramicrofluorometry, after elution.11
The children in the breastfed group were given BM on
demand during intervals between bottle feeds with “special
formula”, every 3 hours. The “special formula” was free from
phe and contained protein substitute, water, carbohydrates
and lipids. The calorie concentration of the “special formula”
was kept at around 67 cal/100mL. The volume of BM and the
quantities of protein substitute and theother ingredientswere
defined according to blood phe levels, tested at each consul-
tation, andwhich should bemaintainedwithin the range con-
sidered adequate for the first year of life.5
The method used to increase or reduce suckling at the
breast and, consequently, to control phe intake,was tomodify
the volume and/or calorie concentration of the ”special for-
mula”. Themodifications were carried out in accordance with
the following criteria:
1) If the phe assay was normal, then the volume and ingre-
dients of the “special formula” were left unaltered.
2) If the phe assay result was > 6 mg/dL, then the “special
formula” was altered, and the volume of each bottle feed
was increased in the following manner: by 10 to 20 mL
when phe was > 6mg/dL and≤ 8mg/dL, by 20 to 40mL
when phe was > 8 mg/dL and ≤ 10 mg/dL, and by 40 to
50 mL when phe was > 10 mg/dL. In the event that phe
assay results were > 6 mg/dL at three consecutive con-
sultations, then BM would be withdrawn and traditional
treatment started.
3) If the phe assay results were < 2mg/dL, the volume and
ingredients of the “special formula” for each bottle feed
were reduced by 10mL, in order to stimulate suckling at
the breast and increase BM intake, until the phe levels
reached recommended levels or until the volumeof “spe-
cial formula” reached a minimum of 20 mL/feed. If the
volume reached this minimum, without increasing blood
phe levels, for two consecutive consultations, then the
calorie concentration of the “special formula” was
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reduced from 67 to 45 cal/100 mL. If blood phe levels
continued at < 2mg/dL, then commercial infant formula
containing phewas added to the “special formula”,whilst
maintaining the BM.
The children in the control group were given milk-based
commercial infant formula as their phe source, the amino acid
profile of which is known. The “special formula” diet was pre-
scribed for 24 hours, given in a bottle every 3 hours, and con-
tained protein substitute, lipids and carbohydrates in addition
to the commercial infant formula. At subsequent consulta-
tions, the quantity of commercial infant formula was altered
depending on blood phe levels, while the concentration of the
“special formula” was maintained at around 67 cal/mL.
For thebreastfedgroup, theduration of breastfeedingwas
calculated and an analysismade of the number of children for
whom itwasnecessary to introduce the commercial infant for-
mula in order to maintain blood phe levels within recom-
mended limits.
The characteristics of the twogroupswere comparedusing
the Wilcoxon test, with the level of significance defined as
p < 0.05.
The mean of blood phe assays results were analyzed, for
both groups, throughout the period duringwhich the children
were being breastfed, with the exception of assays per-
formed before starting treatment and on the day that the tol-
erance testwas performed. The test is carried out at 6months
for diagnostic confirmation PKU classification.
Blood phe levels were grouped monthly at < 2 mg/dL;
≥ 2 mg/dL and ≤ 6 mg/dL and > 6 mg/dL for both breastfed
and control groups.
The two groups were compared in terms of mean time (in
days) to reach normal blood phe levels, using the Wilcoxon
test, with the level of significance set at p < 0.05.
Thenutritional status of the twogroupswas classifiedwith
the aid of Epi-Info (epinut), taking the z score≥ -2 as the cut-
off point betweenwell-nourished andmalnourished children.
Measurements of the weight, stature and head circumfer-
ence of each child were taken on the day of the first consulta-
tion and on the day, or the closest day possible to the day on
which breastfeeding ceased. For the control group, the same
measurements were also taken on the day of the first consul-
tation and on the day corresponding to the age at which their
pair had ceased BM. The anthropometric indices were com-
pared with Student’s paired t test using SPSS.
Results
Twenty-one (60%) of the 35 children in each group were
male.
Table 1 contains the characteristics of the breastfed and
control groups and a comparison of the time needed (in days,
from the start of treatment) for their blood phe levels to reach
the range of normality. It can be observed that there were no
significant differences between the groups.
The mean duration of breastfeeding over the 12 months
of follow-upwas224.4±120.1days,withamedianof 199days
and a variation of 35 to 365 days. The numbers of children
being breastfed, month by month, are illustrated in Figure 1.
It was necessary to introduce commercial infant formula
to the diets of 24 (68.5%) children, a mean of 75.4±52 days
after the start of treatment, in order to complete their phe
intake,maintainingbreastfeedingand levels of the aminoacid
in blood within recommended limits.
Figure 2 illustrates themeans and standard deviations for
the blood phe levels of each child in the breastfed and control
groups over the study period, itself determined by duration of
breastfeeding. Note that one child in the breastfed group and
Table 1 - Comparison of the characteristics of the breastfed and control groups and the time (days) taken to normalize phe blood levels after
starting treatment
Breastfed group (n = 35) Control group (n = 35)
p25 Median* p75 p25 Median* p75 p
†
Birth weight (kg) 2.8 3.2 (2.6-4.2) 3.4 2.8 3.0 (2.5-3.9) 3.4 0.41
Blood phe at neonatal screening (mg/dL) 14.4 18.9 (5.3-45.3) 25.7 14.5 18.8 (6.0-48) 24.7 0.92
Blood phe at 1st consultation (mg/dL) 19.7 28.4 (11.5-47.9) 33.9 21.2 27.1 (11.8-48) 33.9 0.86
Age at screening test (days) 5 7 (4-25) 9 5 6 (4-19) 13 0.54
Age at 1st consultation (days) 19 23 (15-39) 26 21 24 (12-39) 33 0.08
Time (days) to normalize phe levels
after starting treatment 7 8 (6-35) 14 7 7 (5-21) 14 0.47
p25 = 25th percentile; p75 = 75th percentile; phe = phenylalanine.
* Median (minimum-maximum).† Wilcoxon test for differences between medians.
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two in the control group exhibited mean blood phe levels
≥ 6 mg/dL.
After analysis of the blood phe assays, we found that
30.9%of the 695 tests of children in the breastfed groupwere
<2mg/dL, 56.1%were≥2mg/dL and≤6mg/dL and13.8%
were > 6 mg/dL. In the control group, 34.9% of the 704 test
resultswere<2mg/dL, 39.5%were≤6mg/dLand≥2mg/dL
and 25.6% were > 6 mg/dL.
Table 2 contains a comparison of the two groups in terms
of mean anthropometric indices at initial and final assess-
ments. It was observed that there were no significant differ-
encesbetweenanyof themeansof theanthropometric indices
analyzed, either at start of treatment or at breastfeeding ces-
sation, considering a 95% confidence level. At initial anthro-
pometric assessment, one child in the breastfed group
presented with a z score≤ -2 for the weight/age and stature/
age indices and another child did so for the stature/age index.
In the control group, two children presented with a z score
≤ - 2: one for the weight/age index and the other for stature/
age. At their final assessments, one of the breastfed children
hadaz score≤ -2 forweight/statureandoneother for stature/
age; none of the children in the control group had a z score
≤ -2.
The analysis of anthropometric follow-up (difference
between final and initial assessments) for the breastfed and
control groups demonstrated good progress in all indices in
both groups; in the breastfed group, statistical significance
was only detected in the difference in stature/age ratio
(p = 0.00); in the control group statistical significance was
detected in the change in stature/age ratio (p=0.00) and the
difference in weight/age ratio (p = 0.00).
On the day of the first consultation,meanhead circumfer-
ence in the breastfed group was 35.9±1.4 cm and in the con-
trol group it was 36.1±1.4 cm. There was no significant
difference between the groups (p = 0.7). This analysis was
based on31pairs of observations, as a result of a lack ofmea-
surements for some of the children in the control group.
At the final head circumference assessment, the breast-
fed group has ameanmeasurement of 44.0±3.4 cm, and the
control groupmeanwas 44.0±2.9 cm, oncemorewith no sig-
nificant difference between the groups (p = 0.8).
The evolution of head circumference, the difference
between the final and initial measurements, was 7.9±3.1
(p = 0.0) in the breastfed group. In the control group this dif-
ference was 7.7±2.7 (p = 0.0). It will be observed that the
childrenprogressed favorably and that thedifferencewas sta-
tistically significant for both groups.
Discussion
Thepossibility ofmaintainingnatural breastfeeding as the
source of phe in PKU treatment means that phenylketonuric
infants can be offered all the advantages of BM, even if they
are receiving it as part of a mixed breastfeeding. Among oth-
ers, emphasis is due to the emotional advantages that the act
of breastfeeding provides, both in strengthening the emo-
tional bond between mother and child and in acceptance of
disease.
10,12 However, in order that the use of BM is effective
for treatment of PKU, patients must attend frequent visits at
Table 2 - Comparison of the breastfed and control groups in terms
of the means of anthropometric indices, at first consulta-
tion and at the end of breastfeeding
Index Group
Z score
Mean ± SD p*
Initial assessment
Weight/stature
(n = 30) Breastfed 0.00±0.77 0.49
Control 0.11±0.73
Weight/age
(n = 35) Breastfed -0.46±0.79 0.78
Control -0.51±0.72
Stature/age




(n = 35) Breastfed 0.11±0.90 0.72
Control 0.19±0.86
Weight/age
(n = 35) Breastfed -0.14±0.99 0.19
Control 0.13±0.95
Stature/age
(n= 35) Breastfed -0.29±1.01 0.24
Control -0.02±1.02
SD = standard deviation.
* Student’s t test.
Figure 1 - Distribution, month by month, of the number of chil-
dren being breastfed over the 12 months of follow-up,
after the start of treatment
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specialist centers, making possible constant dietary adjust-
ments and adequate metabolic control, avoiding undesirable
blood phe levels.6-9,13-15
Even in the presence of certain risk factors for definitive
weaning, which are inevitable in this situation, we consider
that the breastfeeding duration of the children with PKU was
very good and that it was comparable to the mean durations
described in the literature, both for children with PKU and for
Brazilian children without PKU.13,16,17 Demirkol et al.,13
McCabe et al.10 and Motzfeldt et al.6 foundmean breastfeed-
ing duration in phenylketonuric patients of 6.1, 8.9 and 7.0
months, respectively. However, in a study by Rijn et al.,7
breastfeeding duration was just 2.5 months. None of these
authors make it clear whether their definition of breastfeed-
ing duration included the period of breastfeeding before start-
ing treatment. In our study this period was not included and,
if it had been included in statistical analysis, we would have
observeda longermeanbreastfeedingduration than reported
here. Although the breastfeeding duration of observed was
below that recommended by the World Health Organization,
one should take into account the fact that, when traditional
treatment is used, children are definitivelyweanedduring the
first month of life. By maintaining BM in these phenylketonu-
ric infants’ diets, they benefit for a longer period which,
according to the results of this study, can vary from 30 to 365
days after starting treatment.
The time needed from the start of treatment for blood phe
levels to reach normal levels is very important. In this study
we observed that the results of the two groups were statisti-
cally similar. Rijn et al.7 observed a mean time of 6 days for
the amino acid to reach normal levels in the blood, in both
groups. These authors assayed blood phe daily, and BM was
given once a day, with feeds increased as phe levels reduced.
Motzfeldt et al.6 reported a mean of 8 days for their patients’
blood phe to reach normal levels and, in their study, BM was
withdrawn for 1 to 3 days. We should point out that, in our
study, when calculating the time needed for blood phe levels
to reach normal, a minimum period of 5 days after start of
treatment was used, since the biochemical assays were per-
formedweakly on the day of the consultation. Daily blood phe
assays are not viable in developing countries, such as Brazil,
because of the elevated cost of the procedure. The same
explanation is applicable to theoption ofwithdrawingBM tem-
porarily, at the start of treatment, which has been performed
in somestudies, butwhich requires hospital admission.6,7Our
greatest initial concern when we implemented the use of BM
for PKU was whether it would be possible to maintain blood
levelswithin recommended limits. Analyzingofmeanmonthly
ph blood measurements, during the period in which the chil-
drenwere being breastfed,we observed that for both groups,
the majority of levels remained within the limits recom-
mended by the literature.5 We also observed that the breast-
fedgroupexhibited less variability in termsof test results than
the control group. When the blood phe levels of each child
were analyzed, we observed a greater monthly proportion of
normal test results in the breastfed group, when compared
with the control group. This proportional analysis of blood phe
levels was merely descriptive, since the number of tests for
each child differed between groups, making statistical com-
parison impossible because of the likelihood of bias. Rijn et
al.7 compared theproportionsof bloodphe levels between two
groups, breastfed and control, and concluded that there was
no statistical difference between them. However, the authors
did not make it clear whether or not they compared an equal
number of tests for the two groups. In our study, themajority
of blood phe levels remained within limits considered safe
throughout the period during which the children were being
breastfed.
When we analyzed the pondero-statural growth of these
children, we observed, in our statistics, that the majority of
the children studied had a z score > -2, when the breastfed
and control groups were compared, with no statistical differ-
ence between them. Analyzing the anthropometric evolution
Figure 2 - Means and standard deviations of phenylalanine blood levels of each of the 35 children in the control and breast-
fed groups, over the follow-up period
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of the breastfed group, we found that all of the indices
assessedhad improved,with statistical significance in the case
of the stature/age index. Children in the control group also
improved, although only the change in weight/stature ratio
did not exhibit statistical significance. Head circumference
grew at an appropriate rate, with significant progress and
similar results for both groups. Maintaining breastfeeding
while treating PKUmadeadequate growthpossible during the
breastfeeding period and the children developed in line with
the reference standard for their age, confirming the findings
of published literature.6-10,14
Although the two groups were selected during distinct
periods, we did not observe any implication of this that could
have affected the research results. The protocol used at the
SEG-HC-UFMGand the treating teamwere the same through-
out the study.
We conclude that it is possible to use BMas the phe source
in PKU treatmentwhilstmaintaining adequate control of blood
phe levels and keeping patient growth within normal limits.
In the specific case of PKU, it should be added that, among all
thebenefits inherent to the conduct describedhere, that there
is positive reinforcement of themother-baby emotional bond,
which has a positive impact on acceptance of the disease and
compliance with treatment.
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